Policy Analysis: Investment, Life Sciences
Horizon 2020 Special Coverage
Horizon 2020 – New Commission, new Agenda
The 2015 Science|Business Horizon 2020 Conference
- 24 March 2015
The EU Energy Challenge: Can innovation fill the gap?
The EU’s transition to a sustainable energy system is a top policy challenge of the coming decade. Though much progress has been achieved, the pace of change is too slow.
Square - Brussels Meeting Centre - 13 November 2014
Heathcare biotech: New ideas for a healthier, wealthier Europe

European Parliament, Brussels - 09 October 2014
Helping Europe Innovate
The Annual Report 2013-2014 is a summary of the activites of the Science|Business Innovation Board over the past year. The Science|Business...
Published:
UCL spin out sold to Amgen in $1 billion deal

University College London cancer vaccines spin-out BioVex has been bought by US biotech company Amgen in deal worth up to $1 billion.


BioVex, a cancer vaccines specialist spun out of University College London (UCL) is being acquired by US biotechnology giant Amgen in an all-cash deal worth up to $1 billion. Amgen is paying $425 million upfront, with a further $575 million to come on reaching some clinical and regulatory milestones.

The acquisition is a welcome return for the venture capital (VC) investors who have supported the company through six private rounds of investment, since it was formed in...



Related subjects: Cancer

Advertisement